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a window of opportunity trial “hypoxia scan-nitroglycerin – 
hypoxia scan” (ClinicalTrials.gov Identifier: NCT01210378) 
and in the lab with a cellular respiration assays measuring 
Oxygen consumption (OCR) and extracellular acidification 
(ECAR) using Seahorse XF96 extracellular Flux analyser.  
Currently 19 patients have received their baseline HX-4 scan 
of which 14 patients received a second nitroglycerin scan as 
well. The median interval between the baseline and 
nitroglycerin scans was 4.5 days (range 2-7 days). 
We found that Nitroglycerin significantly decreases the 
hypoxic fraction in all investigated non-small cell lung cancer 
tumours and metastatic lymph nodes. Our lab work 
demonstrate that nitroglycerin has an inhibitory effect on 
mitochondrial respiration which by decreasing oxygen 
consumption increase the availability of oxygen and decrease 
hypoxia.  
This promising result encourages further investigation of 
nitroglycerin as a radio-sensitizing agent using hypoxia 
imaging as biomarker for selection. 
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Introduction: We have previously shown that αvβ3 integrins 
control radioresistance, hypoxia and angiogenesis and that 
co-expression of FGF-2 and  αvβ3 integrins in the tumors of 
patients treated with exclusive radio-chemotherapy for stage 
III non-small lung carcinoma (NSCLC), was associated with a 
worse local control, suggesting that inhibition of αvβ3 
integrin could induce a radiosensitization of such tumours. 
We designed a phase I trial associating the specific 
αvβ3/αvβ5 integrin inhibitor Cilengitide with radio-
chemotherapy in patients with stage III NSCLC.  
Patients and methods: A standard 3+3 dose escalation design 
was used. Cilengitide was given in continuous infusion 
starting 2 weeks before and then during the whole course of 
the radio-chemotherapy (66 Gy combined with a Platine-
Navelbine regimen), and then at a dose of 2000 mg twice a 
week in association with chemotherapy. Planed Cilengitide 
continuous infusion dose levels were 12, 18, 27 and 40 mg/h. 
PET-FDG and CT scan were performed before and then after 
the first two weeks of Cilengitide administration and then 2 
months after the end of radio-chemotherapy. Patients were 
followed by CT scan. Toxicity for DLT was assessed during 
combined treatment and until 1 month after. Clinical 
response on CT scan and TEP was evaluated according to 
RECIST and PERCIST criteria.  
Results: Fourteen patients were included between March 
2010 and July 2013. Eleven patients were evaluable for DLT. 
No DLT was observed at level 0, 1 and 2. One DLT, a  
tracheo-bronchial fistula was reported at the 40 mg/h dose. 
No relevant adverse event related to Cilengitide (7 grade 1 
and one grade 2) was observed on the whole population. 
Among 11 patients evaluable for efficacy, 9 patients 
presented a partial response and 2 a stable disease. At 12 
months after the end of radio-chemotherapy, 4 patients 
presented a progressive disease. At PET evaluation 2 months 
after radio-chemotherapy, 4 patients had a complete 
response and 4 patients had a partial response. 
Conclusion: Cilengitide given continuously with radio-
chemotherapy was well tolerated and shows encouraging 
clinical results, suggesting that targeting αvβ3 integrin 
continuously during radio-chemotherapy in NSCLC is a 
promising approach to treat this disease.  
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Moulds and Flaps are typically used on superficial skin 
brachytherapy for Planning Target Volume (PTV) up to 5 mm 
depth. In the cases of small and flat PTV, the use of 
superficial skin Applicators is an efficient solution because 
they shield the surrounding healthy tissues. In contrast to 
electrons beams applications (where bolus and specific 
dosimetry is required), treatment planning and delivery is 
simpler. 
 There are radionuclide-based HDR Ir-192 Applicators, as the 
Leipzig (Varian and Elekta) and Valencia (Elekta) ones. The 
Valencia Applicators are a modification of the Leipzig ones 
where a flattering filter has been added. Consequently, 
lateral homogeneity, penumbra, and useful beam are 
improved. However treatment time becomes longer. 
 The electronic HDR brachytherapy surface applicators offer 
an alternative to external beam electrons and HDR 
radionuclide brachytherapy modalities. There are currently 
two systems being used clinically: Xoft Axxent® (iCad) with 
50 kVp which has been in use since 2009 , and Esteya® 
(Elekta) with 69.5 kVp which has been released in 2014. We 
will discuss in this presentation our experience with the 
Esteya Unit, regarding commissioning, QA and clinical 
implementation. 
 Esteya is a new brachytherapy Unit designed to obtain dose 
distributions similar to Valencia App with an X-ray source of 
69.5 kVp. It has an adjustable arm and a set of 
interchangeable circular applicators of different diameters 
(10 mm, 15 mm, 20 mm, 25 mm, and 30 mm). Once overall 
absorbed dose, number of fractions, prescription depth and 
applicator size are selected in the console treatment 
planning system, the system presents automatically the 
treatment time. Compared with the Valencia Applicattors 
there are improvements in penumbra, treatment time, 
gradient on PTV and leakage. 
 The following aspects of commissioning will be discussed on 
this presentation: 
Timer: Reproducibility, accuracy and linearity (combined 
with mA) 
Flatness, symmetry and penumbra: Using radiochromic films 
and high spatial resolution array SRS1000 (PTW, Germany) 
HVL: Diode vs. ionization chamber detectors. Comparison of 
different set-ups 
